Open AccessThe Timing of Neural Stem Cell‐Based Virotherapy Is Critical for Optimal Therapeutic Efficacy When Applied With Radiation and Chemotherapy for the Treatment of Glioblastoma
Author(s) -
Tobias Alex L.,
Thaci Bart,
Auffinger Brenda,
Rincón Esther,
Balyasnikova Irina V.,
Kim Chung Kwon,
Han Yu,
Zhang Lingjiao,
Aboody Karen S.,
Ahmed Atique U.,
Lesniak Maciej S.
Publication year - 2013
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2013-0039
Subject(s) - oncolytic virus , glioma , temozolomide , neural stem cell , virotherapy , cancer research , medicine , radiation therapy , stem cell , oncology , biology , tumor cells , genetics
This study established a logical experimental model to recapitulate the complex clinical scenario for the treatment of glioblastoma multiforme (GBM) and tested the compatibility of neural stem cells loaded with oncolytic virus. Data from this report support the testing of CRAd‐S‐pk7‐loaded HB1.F3‐CD cells in the clinical setting and argue for a multimodality approach for the treatment of patients with GBM.